

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number  
**WO 02/36622 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47**,  
C12N 15/12, 15/62, C07K 16/18, C12N 5/10, G01N  
33/566

(21) International Application Number: PCT/US01/32619

(22) International Filing Date: 24 October 2001 (24.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/243,770 30 October 2000 (30.10.2000) US

(71) Applicant (for all designated States except US): **SENO-  
MYX, INC.** [US/US]; Suite 160, 11099 N. Torrey Pines  
Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YAO, Yong**  
[CN/US]; 3614 Caminito Carmel Landing, San Diego,  
CA 92130 (US). **XU, Hong** [CN/US]; 12726 Torrey Bluff  
Drive, #62, San Diego, CA 92130 (US).

(74) Agents: **TESKIN, Robin, L.** et al.; Pillsbury Winthrop  
LLP, 1600 Tysons Boulevard, Mclean, Virginia 22102  
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title:  $G\alpha_q$  PROETIN VARIANTS AND THEIR USE IN THE ANALYSIS AND DISCOVERY OF AGONISTS AND AN-  
TAGONISTS OF CHEMOSENSORY RECEPTORS

(57) Abstract: The invention provides a series of  $G\alpha_q$  rotein variants that functionally couple to sensory cell receptors such as taste  
GPCRs(Trs) and olfactory GPCRs(ORs) in an overly promiscuous manner. According to the invention, the functional coupling can  
be determined, for example, by measuring changes in intracellular IP3, or calcium. In a particular embodiment, the  $G\alpha_q$  protein  
variants can be expressed in mammalian cell lines or *Xenopus oocytes*, and then evaluated using calcium fluorescence imaging and  
electrophysiological recording.



WO 02/36622 A2

## **G $\alpha_q$ PROTEIN VARIANTS AND THEIR USE IN THE ANALYSIS AND DISCOVERY OF AGONISTS AND ANTAGONISTS OF CHEMOSENSORY RECEPTORS**

### **Cross-Reference to Related Applications**

This application claims priority to U.S. Provisional Application No. 60/243,770, filed on October 30, 2000, and is incorporated herein by reference in its entirety.

### **Field of Invention**

This invention relates to G $\alpha_q$  protein variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors, such as G protein coupled receptors involved in sensing of tastants, olfactants, and pheromones.

### **Background of Invention**

Heterotrimeric G proteins, consisting of alpha, beta and gamma subunits, couple ligand-bound seven transmembrane domain receptors (GPCRs or G-protein coupled receptors) to the regulation of effector proteins and production of intracellular second messengers such as cAMP, cGMP, and Ca<sup>2+</sup>. G protein signaling mediates the perception of environmental cues in all higher eukaryotic organisms, including yeast, Dictyostelium, plants, and animals. Agonist-bound sensory receptors catalyze the exchange of GTP for GDP on the surface of the G $\alpha$  subunit to initiate intracellular responses to extracellular signals. Intracellular signaling is mediated through various effector enzymes, including cGMP phosphodiesterase, phospholipase C, adenylate cyclase, etc. (see Kinnamon & Margolskee, 1996, Curr. Opin. Neurobiol. 6: 506-513). Most effector proteins interact with the G $\alpha$ , although G $\beta\gamma$  subunits also contribute to the specificity of receptor-G protein coupling (Xu et al., 1998, J. Biol. Chem. 273(42): 27275-79).

The G protein  $\alpha$  subunits are grouped into four families, G $\alpha_s$ , G $\alpha_i$ , G $\alpha_q$ , and G $\alpha_{12}$  according to their sequence homologies and functional similarities. The G $\alpha_q$  family members couple a large group of GPCRs to phospholipase C. Activation of G $\alpha_q$  coupled GPCRs induces intracellular calcium release and the capacitative calcium entry from extracellular space. The consequential increase of cytosolic calcium concentration can be effectively detected by using synthetic or genetically-engineered fluorescent

calcium indicators, bioluminescent calcium indicators, calcium-activated ion currents, and by monitoring calcium-regulated gene transcription. Assays based on such calcium readout are available in high-throughput screening (HTS) format.

Signaling specificity among  $\alpha$  subunits of the same class having similar biochemical functions is not well understood *in vivo*. For instance, the  $G\alpha_q$  ( $G_q$ ) class includes four proteins expressed in mammals, called  $G\alpha_q$ ,  $G\alpha_{11}$ ,  $G\alpha_{14}$ , and  $G\alpha_{15}$  (in mice,  $G\alpha_{16}$  in humans). Whereas orthologs of these subunits are highly conserved across species (99, 97, 96 and 85% identity, respectively), paralogs of these subunits (expressed in the same species) are not as conserved. This suggests that each type of subunit in the  $G_q$  class has a distinct function, however, when transfected into Sf9 cells, the subunits stimulated phospholipase C with similar potency and showed similar activities (Nakamura et al., 1995, J. Biol. Chem. 270: 6246-6253). Xu and colleagues subsequently showed by gene knockouts in mice that  $Gq_\alpha$  subunits promiscuously couple to several different receptors in various cell types (1998, J. Biol. Chem. 273(42): 27275).

The promiscuity of the  $G\alpha_q$  subclass of G protein subunits provides a valuable tool for analyzing the role of G protein complexes and GPCRs in chemosensory transduction. For instance, the ability of  $G\alpha_q$  proteins to bypass the selectivity of the receptor G-protein interaction can be used to study the molecular mechanism of receptor-induced G-protein activation. In addition, the promiscuity toward receptors may be helpful in identifying ligands corresponding to orphan receptors whose signaling properties are unknown. Promiscuous G protein subunits play a particularly useful role in generating screening assays for high affinity GPCR agonists, antagonists, and modulators of chemosensory activity, in that using a single G protein coupler removes the variability of the G protein from the equation, thereby simplifying interpretation of results gleaned from various modulating compounds and GPCRs. Chemosensory modulating compounds involved in taste and/or smell, for instance, could then be used in the pharmaceutical and food industries to customize taste or aroma. In addition, such chemosensory molecules could be used to generate topographic maps that elucidate the relationship between the taste cells of the tongue or olfactory receptors (Ors) and sensory neurons leading to the brain.

Despite their promiscuity, however,  $G\alpha_q$  class subunits do not mediate all GPCR – effector interactions. For instance, human  $G\alpha_{16}$  and its murine counterpart  $G\alpha_{15}$  are promiscuous G proteins in that they couple to GPCRs of different G protein families (Offermanns and Simon, 1995; Negulescu et al., 1997). However, they are not true universal adapters for GPCRs in that there are at least 11 GPCRs reported to be incapable of activating  $G\alpha_{15}/G\alpha_{16}$  (Wu et al., 1992; Arai et al., 1996; Kuang et al., 1996; Lee et al., 1998; Parmentier et al., 1998; Mody et al., 2000). Similar problems arise when using  $G\alpha_{15}/\alpha_{16}$  to identify ligands of ORs and T2Rs (bitter taste receptors) in that (1) calcium responses to odorants are small and quickly desensitized for ORs in  $G\alpha_{15}/\alpha_{16}$  transiently transfected cells (Krautwurst et al., 1998); (2) most T2Rs remain orphan using cell lines stably transfected with  $G\alpha_{15}$  (Adler et al., 2000; Chandrashekar et al., 2000); and (3) threshold concentration of denatonium measured is at least one order higher than expected for bitter receptors, hT2R4 and mT2R8 expressed in cells stably transfected with  $G\alpha_{15}$  (Adler et al., 2000; Chandrashekar et al., 2000). These problems suggest that the coupling efficiency between ORs/T2Rs and  $G\alpha_{15}/\alpha_{16}$  is weak and may vary within the family of ORs and T2Rs.

Given the partial promiscuity of  $G\alpha_q$  class proteins, it would be desirable to identify or create  $G\alpha$  protein subunits that are more promiscuous than their native counterparts, and which are capable of interacting with a wider variety GPCRs.

### **Summary of Invention**

The present invention addresses the above described problems associated with using  $G\alpha_{15}/\alpha_{16}$ , as well as other problems known in the art relating to the use of weakly promiscuous  $G\alpha$  proteins. Generally, the invention provides a series of  $G\alpha_q$  ( $G_q$  class) protein variants that functionally couple sensory cell receptors such as taste GPCRs (TRs) and olfactory GPCRs (ORs). According to the invention, the functional coupling can be determined, for example, by measuring changes in intracellular IP3 or calcium. In a particular embodiment, the  $G_q$  protein variants can be expressed in mammalian cell lines or *Xenopus* oocytes, and then evaluated using calcium fluorescence imaging and electrophysiological recording.

In one aspect of the invention, G alpha class q ( $G_q$ ) variants that are capable of widely promiscuous functional coupling to chemosensory receptors, such as taste and olfactory receptors, and isolated nucleic acid sequences encoding the same are provided. Another aspect of the invention is directed to chimeric  $G_q$  variants and the isolated nucleic acids encoding the same. In one embodiment, the chimeric  $G_q$  protein variants comprise C-terminal sequences from transducin or  $G\alpha_{olf}$ , which exhibit improved functional coupling to taste and olfactory receptors, respectively.

In yet another aspect of the invention, a method for the analysis and discovery of agonists and/or antagonists of chemosensory receptors using the  $G_q$  protein variants is provided. One embodiment is directed to a mammalian cell-based assay using a transiently transfected gene or cDNA encoding a  $G_q$  protein variant. Another embodiment is directed to a mammalian cell-based assay using a stably expressed gene or cDNAs encoding  $G_q$  protein variants. In yet another embodiment, a method for analysis and discovery of agonists and/or antagonists of chemosensory receptors in *Xenopus* oocytes using genes, RNAs or DNAs encoding  $G_q$  protein variants is provided. The agonists and/or antagonists discovered using the disclosed assays are also encompassed, as are antibodies which bind specifically to the  $G_q$  variants described herein, but not those which also bind to known  $G_q$  proteins.

Other aspects of the invention relate to expression vectors comprising nucleic acid sequences encoding the  $G_q$  protein variants of the invention, as well as host cells comprising such expression vectors. Further aspects of the invention will become apparent to one of skill in the art from the following detailed description and examples.

### **Brief Description of the Figures**

Figure 1 illustrates the alignment of amino acid sequences of human  $G\alpha_q$ ,  $G\alpha_s$  and  $G\alpha_{16}$  by the Clustal method.

Figure 2 illustrates the amino acid sequences of mouse and human  $G\alpha_q$ . Significant amino acids described herein are boxed and differences between human and mouse are underlined.

Figure 3 illustrates the amino acid sequences of mouse and human  $G\alpha_q$  proteins according to the invention. The variations of the amino acids of  $G\alpha_q$  are depicted in parenthesis. The sequence numbers of amino acid H or Q, V or L are 28 and 29

respectively. The sequence number of amino acid G or D is 66. Truncation of N-terminal six amino acids (MTLESI) are shown as  $\Delta N$ . Hemagglutinin (HA) epitope tag (DVPDYA) spans from 125 to 130. C-terminal five amino acids (-t5) or 44 amino acids (-t44) of transducin and five amino acids of  $G\alpha_{olf}$  (-olf5) are used respectively to replace those of  $G\alpha_q$ .

Figure 4 illustrates additional amino acid sequences according to the invention.

### **Detailed Description of the Invention**

As described above, there are known problems with the use of  $G\alpha_{15}/G\alpha_{16}$  to couple chemosensory receptors in that the coupling efficiency between ORs/T2Rs and  $G\alpha_{15}/\alpha_{16}$  is weak and may vary within the family of ORs and T2Rs (bitter taste receptors). As such, the invention provides a series of  $G_q$  protein variants that functionally couple sensory cell receptors such as taste GPCRs (TRs) and olfactory GPCRs (ORs) in a promiscuous manner. According to the invention, “promiscuous” or “promiscuity” refers to the ability to functionally couple to more than one taste GPCRs and/or olfactory GPCRs. “Increased promiscuity” or “widely” promiscuous refers to the ability to functionally couple to more taste GPCRs and/or olfactory GPCRs than would be demonstrated by the native  $G_q$  protein.

The term “ $G_q$ ” as used herein encompasses all the  $G\alpha_q$  subclasses, including  $G\alpha_q$ ,  $G\alpha_{11}$ ,  $G\alpha_{14}$ , and  $G\alpha_{15}$  (in mice,  $G\alpha_{16}$  in humans). However, the chimeric promiscuous or widely promiscuous  $G_q$  proteins described herein may have sequences incorporated from other  $G\alpha$  class proteins, for instance, from  $G\alpha_s$ ,  $G\alpha_i$  and  $G\alpha_{12}$ . The existing variation between members of the  $G_q$  class could be utilized in combination with the characteristic of promiscuity to generate promiscuous  $G_q$  proteins having altered or new receptor specificities. Protein sequence similarity between  $G\alpha_q$  and  $G\alpha_{15}/G\alpha_{16}$  is less than 57% (Fig. 1). Accordingly, such high divergence should result in significant differences in efficiency and selectivity of receptor coupling. The identification of functionally active  $G_q$  protein variants could allow for the pharmacological and genetic modulation of sensory transduction pathways.

For example,  $G_q$  protein variants could enable screening for high affinity agonists, antagonists, inverse agonists, and other modulators of sensory cell

transduction and activity. Such sensory cell modulators could then be used in the pharmaceutical and food industries to customize sensory perceptions. In addition Gq protein variants could serve as tools in the generation of sensory topographic maps.

According to the invention, Gq protein variants include variants having point mutations that increase promiscuity with regard to GPCR coupling. For instance, the inventors have found that mouse  $G\alpha_q$  variants comprising a Gly to Asp change at position 66 (G66D) demonstrate increased promiscuity. Similar mutations are predicted to have a similar effect on the activity of the corresponding human  $G\alpha_{16}$  subunit given the level of homology and similar activity demonstrated between the two proteins. The mutation G66D is localized at linker 1 region between helices  $\alpha 1$  and  $\alpha A$  of  $G\alpha_q$  (Lambright et al., 1996). For reference, the amino acid sequences for mouse and human  $G\alpha_q$  are listed in Figure 2.

It was found by functional analysis using single-cell calcium imaging that activation of multi-family GPCRs evoked increases in cytosolic calcium in the presence of the  $G\alpha_q$  variants with the G66D mutation. These GPCRs include  $G\alpha_s$ -coupled  $\beta$ -adrenergic receptor,  $G\alpha_{olf}$ -coupled mouse I7 olfactory receptor,  $G\alpha_i$ -coupled m2 muscarinic receptor, and gustducin-coupled bitter receptor mT2R5. No significant change in cytosolic calcium could be detected by activation of the above GPCRs in the absence of the  $G\alpha_q$  variants. Additional GPCRs can include those disclosed in U.S. Patent Application No. 09/510,332 filed February 22, 2000; and U.S. Provisional Application Nos. 60/213,849 filed June 23, 2000; 60/209,840 filed June 6, 2000; 60/195,536 filed April 7, 2000; 60/195,534 filed April 7, 2000; 60/195,532 filed April 7, 2000; which are herein incorporated by references for all purposes in a manner consistent with this disclosure.

Thus,  $G\alpha_q$  variants according to the invention can comprise amino acid substitutions at or near position 66, or at any other position that results in an increase of promiscuity by the variant  $G\alpha$  protein. Other  $G_q$  subclass variants can be designed having similar mutations. Mutations can be identified and isolated using site directed or random mutagenesis according to techniques that are known in the art, including random saturation mutagenesis around the mutation sites described herein. The variants may comprise these one or more of these mutations alone or in combination

with C-terminal substitutions. In another embodiment of the invention,  $G_{\alpha_q}$  and other  $G_q$  subclass variants comprise C-terminal sequences derived from other G proteins.

For instance, the present inventors have also discovered that the Gly to Asp mutation is synergistic with the replacement of the C-terminus of  $G_{\alpha_q}$  by that of transducin or  $G_{\alpha_{olf}}$ .  $G_{\alpha_q}$  proteins containing C-terminal amino acids from transducin or  $G_{\alpha_{olf}}$  in combination with a Gly66 to Asp alteration show increased activity compared to individual chimeras alone. A preferred embodiment is a variant  $G_q$  proteins having at least about five amino acids in the C terminus of said  $G_q$  protein replaced by at least about five amino acids from the C terminus of  $G_{\alpha_{olf}}$  or transducin, wherein said C-terminal substitution increases promiscuity of said variant  $G_q$  protein as compared to the corresponding native  $G_q$  protein. Up to 44 amino acids of the C terminus of transducin or  $G_{\alpha_{olf}}$  may be incorporated. Other possible variants are shown in Figures 3 and 4.

Other mutations and substitutions are envisioned to be within the scope of the invention. For instance, it would be within the level of skill in the art to perform additional amino acid substitutions at other amino acid positions using known protocols of recombinant gene technology including PCR, gene cloning, site-directed mutagenesis of cDNA, transfection of host cells, and in-vitro transcription. The variants could then be screened for functional coupling to chemosensory receptors as described herein. Further, additional C-terminal substitutions could be made from other G-protein molecules known in the art.

The present invention also includes isolated  $G_{\alpha_q}$  subunit polypeptide variants comprising polypeptides with greater than 80% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26. More preferably, variants comprising polypeptides with greater than 90% amino acid sequence identity are included, with the most preferable homologs being at least about 95% identical to the variants described herein.

The invention also includes isolated nucleic acid sequences encoding the  $G_q$  protein variant polypeptides of the invention. Included are isolated nucleic acid sequences comprising a nucleic acid encoding a polypeptide with greater than 80% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26. More preferably, the isolated nucleic acid sequence encoding a  $G_{\alpha_q}$



protein variant comprises a nucleic acid encoding a polypeptide with greater than 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26. Most preferred are isolated nucleic acid sequences encoding  $G\alpha_q$  protein variants which comprise a nucleic acid encoding a polypeptide with greater than about 95% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26.

The terms “identical” or “percent identity” in the context of two or more protein or nucleic acid sequences refers to sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or designated region, using either a sequence comparison algorithm that is known in the art or by manual inspection. Sequences with over 80% sequence identity are said to be “substantially identical.” Optionally, the identity, exists over a region that is at least about 25-30 amino acids or nucleotides in length, or optionally over a region that is 75-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. A “comparison window” as used herein includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 25 to 500, usually about 50 to about 200, more usually about 100 to 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences are well known in the art (see, e.g., Smith and Waterman, 1981, *Adv. Appl. Math.* 2: 482, Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443, Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85: 2444, and *Current Protocols in Molecular Biology*, Ausubel et al., 1995 Suppl.).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity, and can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux et al.,

1984, Nuc. Acids Res. 12: 387-395). Another example of an algorithm that is suitable for determining percent sequence identity is the BLAST or BLAST 2.0 algorithm described in Altschul et al., 1977, Nuc. Acids Res. 25: 3389-3402 (1977) and Altschul et al., 1990, J. Mol. Biol. 215: 403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

Also included in the present invention are antibodies that selectively bind to the variant G<sub>q</sub> alpha proteins described herein, but not to the corresponding native G<sub>q</sub> alpha protein. Such antibodies include whole, chimeric, humanized, tetramer, single chain, domain-deleted and other recombinant antibodies of any immunoglobulin class, as well as antibody fragments, Fv, Fab', (Fab')<sub>2</sub>, etc. Preparation of such antibodies may be performed using any method known in the art (see, e.g., Kohler and Milstein, 1975, Nature 256: 495-97; Kozbar et al., 1983, Immunology Today 4: 72; Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, 1985). Mice or other animals may be immunized with the G<sub>q</sub> protein variants of the invention in order to generate antibodies, which may be screened to identify those specific for the G<sub>q</sub> variants of the invention which also do not recognize the corresponding native G<sub>q</sub> protein.

The present invention also encompasses expression vectors comprising the nucleic acid sequences of the present invention operably linked to a promoter that functions in mammalian cells or *Xenopus* oocytes. A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. A "promoter" includes all the necessary sequences near the start site of transcription, i.e., including a polymerase binding site. A promoter optionally includes distal enhancer or repressor elements which can be located as much as thousands base pairs away from the start site of transcription. Promoters may be either constitutive, i.e. active under most environmental and developmental conditions, or inducible, i.e., under specific environmental or developmental control. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter) and a second nucleic acid sequence, such as one encoding a variant G<sub>q</sub> protein as described in the present invention, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence. An "expression vector" is a nucleic acid construct comprising a coding nucleic acid

sequence according to the invention operably linked to a promoter, which allows for recombinant production of the variant G<sub>q</sub> proteins described herein. Expression vectors encompassed by the invention can be either incorporated into the genome of a host cell after transfection, or replicate extrachromosomally. Expression vectors can be either plasmids, viruses or nucleic acid fragments. Alternatively, coding sequences can be incorporated into the genome behind a native promoter, thereby creating an operable expression linkage following transfection. Host cells transfected with the expression vectors of the invention are also encompassed.

The present invention also includes methods for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of: (1) contacting the compound with a cell expressing the G<sub>q</sub> variant protein according to claim 1; and (2) determining the functional effect of said compound upon the G<sub>q</sub> protein variant. Typically, a cell expressing said G<sub>q</sub> variant protein is a transfected sensory cell, or other transfected cell suitable for making functional measurements of G protein activity, i.e., *Xenopus* oocyte. Functional effects of possible modulatory compounds may be determined by measuring changes in intracellular IP3 or Ca<sup>2+</sup>. Functional effects may also be determined by measuring changes in the electrical activity of the cells expressing said G<sub>q</sub> variant protein or by observing modification of an intracellular effector enzyme. Possible modulatory compounds include agonists, antagonists, antibodies, small molecules and proteins.

Also included in the invention are methods for identifying a compound that interacts with the G<sub>q</sub> variant protein of claim 1, comprising the steps of (1) contacting said G<sub>q</sub> variant protein with a test compound; and (2) detecting a binding interaction between said compound and said G<sub>q</sub> protein variant. Methods of detecting the binding of G<sub>q</sub> protein variants to compounds can be performed wherein said G<sub>q</sub> variant protein is linked to solid phase, either covalently or noncovalently.

The present invention also includes an artificial array of GPCRs functionally coupled to the G<sub>q</sub> variant of claim 1, wherein said array is a model of a native arrangement of GPCRs. For instance, the native arrangement can be an arrangement of olfactory receptors (ORs) typically seen in a mammalian nose, or an arrangement of taste receptors typically seen on a mammalian tongue. Said taste receptors typically include at least one type of taste receptor selected from the group consisting of bitter,

sweet, salty, unami and sour taste receptors, in light of the observations that such taste receptors are typically arranged in spatially organized manner. The artificial arrays of the present invention are useful for analyzing the response to different sensory compounds in relation to brain activity. Such arrays will be improved by the promiscuous variant  $G_q$  proteins of the present invention, which will simplify interpretation of results that might normally be complicated by the requirement for different G protein subunits for every GPCR in such an array.

It is also envisioned that the  $G_q$  protein variants of the invention could be used in other types of functional assays such as biochemical binding assays, enzymatic assays, other cell-based assay, as well as with in vivo systems such as transgenic mice.

The following examples serve merely to illustrate the invention, and should not be construed as limiting the scope of the invention in any way.

### EXAMPLES

Initially, the  $G\alpha_q$  variant protein termed mGq(ON-HVD-HA) of Seq ID#5, described in Kostenis et al. (1998), was shown to functionally couple to taste receptor mT2R5 and olfactory OR I7. Previously, it had not been known whether this protein would allow functional expression of chemosensory receptors such as taste and olfactory receptors. The response using the Kostenis et al G protein was weak. Therefore, in order to improve functional coupling a series of variants was created. The variants were chimeras between the variants of the Kostenis G protein which contained the C terminal sequences from  $G\alpha_{olf}$  or transducin. Variants containing the C-terminal changes exhibited improved function. The use of C-terminal replacements in G proteins had previously been reported by Conklin (Conklin et al., 1993; Conklin et al., 1996; Coward et al., 1999) but the sequences from  $G\alpha_{olf}$  or transducin had not previously been shown to function with taste or olfactory receptors.

A series of  $G\alpha_q$  protein variants having the sequences listed in Fig. 3 were constructed and tested in mammalian cell-based systems and in *Xenopus* oocytes for functional coupling efficiency with bitter receptor mT2R5 and mouse olfactory receptor I7. As shown in Table I below, one set of G proteins function with a taste receptor and another set of G proteins function with an olfactory receptor. All active G proteins consisted of mouse sequences, however given the similarities between human and

mouse  $G\alpha_q$  proteins, it is anticipated that the human variants will also functionally couple with human chemosensory receptors.

Table I: Functional Activity of Gq Variants

<b>Gq Variants</b>	<b>Seq ID #</b>	<b>Functional Activity With Taste Receptor MT2R5</b>	<b>Functional Activity with Olfactory Receptor mI7</b>
MGq	1	-	N/A
mGq( $\Delta$ N)	2	-	N/A
mGq(HA)	3	-	N/A
mGq( $\Delta$ N-HA)	4	-	N/A
MGq( $\Delta$ N-HVD-HA)	5	+	+
MGq( $\Delta$ N-HVD-HA)-t5	6	++	N/A
MGq( $\Delta$ N-HVD-HA)-t44	7	++	N/A
mGq( $\Delta$ N-HV-HA)	8	-	N/A
mGq(HV-HA)	9	-	N/A
mGq(D-HA)	10	+	N/A
mGq(HVD-HA)	11	+	N/A
mGq(HV-HA)-t5	12	+	N/A
mGq(HVD-HA)-t5	13	++	N/A
mGq( $\Delta$ N-HVD-HA)-olf5	14	N/A	++
HGq	15	-	N/A
hGq( $\Delta$ N)	16	-	N/A

+ means functionally couples with chemosensory receptor

++ means functionally couples with chemosensory receptor

- means does not functionally couple

N/A mean not tested

## References

- Adler et al., 2000, "A novel family of taste receptors," *Cell* 100: 693-702.
- Ari et al., 1996, "Differential regulation of G-protein-mediated signaling by chemokine receptors," *J. Biol. Chem.* 271: 21814-21819.
- Bertin et al., 1994, "Cellular signaling by an antagonist-activated receptor/Gs $\alpha$  fusion protein," *Proc. Natl. Acad. Sci. USA* 91: 8827-8831.
- Chandrashekar et al., 2000, "T2Rs function as bitter taste receptors," *Cell* 100: 703-711.
- Conklin et al., 1996, "Carboxyl-terminal mutations of Gp $\alpha$  and Gs $\alpha$  that alter the fidelity of receptor activation," *Mol. Pharm.* 50: 885-90.
- Coward et al., 1999, "Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors," *Anal. Biochem.* 270: 242-248.
- Kostenis et al., 1998, "Functional characterization of a series of mutant G protein alpha subunits displaying promiscuous receptor coupling properties," *J. Biol. Chem.* 273: 17886-17892.
- Krautwurst et al., "Identification of ligands for olfactory receptors by functional expression of a receptor library," *Cell* 95: 917-26.
- Kuang et al., 1996, "Selective G Protein Coupling to C-C Chemokine Receptors," *J. Biol. Chem.* 271:3975-3978.
- Lambright et al., 1996, "The 2.0 Å Crystal Structure of a Heterotrimeric G Protein," *Nature*, 379: 311-319.
- Lee et al., 1998, "Differential Coupling of  $\mu$ ,  $\delta$  and  $\kappa$  Opioid Receptors to G $\alpha_{16}$ -mediated Stimulation of Phospholipase C," *J. Neurochem.* 70:2203-2211.
- Mody et al., 2000, "Incorporation of G $\alpha_z$ -Specific Sequence at the Carboxyl Terminus Increases the Promiscuity of G $\alpha_{16}$  toward G $_i$ -coupled Receptors," *Mol. Pharm.*, 57:13-23.
- Negulescu et al., 1997, "Promiscuous G-protein Compositions and Their Use," U.S. Patent No. 6,004,808.
- Offermanns & Simon, 1995, "G $\alpha_{15}$  and G $\alpha_{16}$  couple a wide variety of receptors to phospholipase C," *J. Biol. Chem.* 270:15175-15180.

Parmentier et al., 1998, The G protein-coupling Profile of Metabotropic Glutamate Receptors, as Determined with Exogenous G Proteins, is Independent of Their Ligand Recognition Domain," *Mol. Pharmacol.* 53:778-786.

Seifert et al., 1999, "GPCR-G $\alpha$  Fusion Proteins: Molecular Analysis of Receptor-G-Protein Coupling," *TiPS* 20:383-389.

Wu et al., 1992, "Activation of Phospholipase C by  $\alpha$ 1-adrenergic Receptors is Mediated by the  $\alpha$  Subunits of the Gq Family," *J. Biol. Chem.* 267:25798-25802.

**What is claimed:**

1. An isolated variant of a  $G_q$  protein that exhibits increased promiscuity relative to the corresponding  $G_q$  protein.
2. The variant  $G_q$  protein of claim 1, wherein the  $G_q$  protein is of a subclass selected from the group consisting of  $G\alpha_q$ ,  $G\alpha_{11}$ ,  $G\alpha_{14}$ , and  $G\alpha_{15}/G\alpha_{16}$ .
3. The variant  $G_q$  protein of claim 2, wherein said  $G_q$  protein is of the  $G\alpha_q$  subclass.
4. The variant  $G_q$  protein of claim 3, wherein said variant comprises at least one point mutation that increases promiscuity.
5. The variant  $G_q$  protein of claim 4, wherein said mutation is a Glycine to Aspartic acid change at position 66.
6. The variant  $G_q$  protein of claim 1, wherein said variant  $G_q$  protein is derived from a mammalian  $G_q$  protein.
7. The variant  $G_q$  protein of claim 6, wherein said mammalian  $G_q$  protein is derived from a mouse  $G_q$  protein.
8. The variant  $G_q$  protein of claim 6, wherein said mammalian  $G_q$  protein is derived from a human  $G_q$  protein.
9. The variant  $G_q$  protein of claim 1, wherein at least about five amino acids in the C terminus of said  $G_q$  protein are replaced by at least about five amino acids from the C terminus of  $G\alpha_{olf}$  or transducin, and wherein said C-terminal substitution increases promiscuity of said variant  $G_q$  protein as compared to the corresponding native  $G_q$  protein.



10. The variant  $G_q$  protein of claim 9, wherein said variant  $G_q$  protein further comprises at least one point mutation that acts in addition to said C-terminal substitution to increase promiscuity of said variant  $G_q$  protein as compared to the corresponding native  $G_q$  protein.
11. A  $G_q$  chimeric protein comprising at least about five amino acids from the C terminus of transducin, wherein said chimeric protein has binding specificity for olfactory GPCRs and taste GPCRs.
12. A  $G_q$  chimeric protein comprising at least about five amino acids from the C terminus of  $G\alpha_{olf}$ , wherein said chimeric protein has binding specificity for olfactory GPCRs and taste GPCRs.
13. An isolated  $G\alpha_q$  subunit polypeptide variant comprising a polypeptide with greater than 95% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26.
14. An isolated nucleic acid sequence encoding the  $G_q$  protein variant of claim 1.
15. An isolated nucleic acid sequence encoding the  $G_q$  protein variant of claim 11.
16. An isolated nucleic acid sequence encoding the  $G_q$  protein variant of claim 12.
17. An isolated nucleic acid sequence encoding a  $G\alpha_q$  protein variant comprising a nucleic acid encoding a polypeptide with greater than 80% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26.
18. An isolated nucleic acid sequence encoding a  $G\alpha_q$  protein variant comprising a nucleic acid encoding a polypeptide with greater than 90% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26.

19. An isolated nucleic acid sequence encoding a  $G\alpha_q$  protein variant comprising a nucleic acid encoding a polypeptide with greater than 95% amino acid sequence identity to a sequence selected from the group consisting of SEQ ID Nos 1-26.
20. An antibody that selectively binds to the variant  $G_q$  alpha protein of claim 1, but not to the native  $G_q$  alpha protein.
21. An expression vector comprising the nucleic acid sequence of claim 14 operably linked to a promoter that functions in mammalian cells or *Xenopus* oocytes.
22. A host cell comprising the expression vector of claim 21.
23. A method for identifying a compound that modulates sensory signaling in sensory cells, the method comprising the steps of:
  - (i) contacting the compound with a cell expressing the  $G_q$  variant protein according to claim 1; and
  - (ii) determining the functional effect of said compound upon the  $G_q$  protein variant.
24. The method of claim 23, wherein said cell expressing said  $G_q$  variant protein is a transfected sensory cell.
25. The method of claim 23, wherein said cell expressing said  $G_q$  variant protein is a *Xenopus* oocyte.
26. The method of claim 23, wherein the functional effect is determined by measuring changes in intracellular cAMP, IP3 or  $Ca^{2+}$ .
27. The method of claim 23, wherein the functional effect is determined by measuring binding of a radiolabeled GTP to said variant  $G_q$  protein.

28. The method of claim 23, wherein the functional effect is determined by measuring changes in the electrical activity of the cells expressing said  $G_q$  variant protein.
29. The method of claim 23, wherein the functional effect is determined by observing modification of an intracellular effector enzyme.
30. The method of claim 23, wherein said  $G_q$  variant protein comprises sequences of a native  $G_q$  protein from a human or rodent.
31. The method of claim 23, wherein said compound is selected from the group consisting of agonists, antagonists, antibodies, small molecules, and proteins.
32. A method for identifying a compound that interacts with the  $G_q$  variant protein of claim 1, comprising the steps of:
- (i) contacting said  $G_q$  variant protein with a test compound; and
  - (ii) detecting a binding interaction between said compound and said  $G_q$  protein variant.
33. The method of claim 32, wherein said  $G_q$  variant protein is linked to solid phase.
34. The method of claim 32, wherein said  $G_q$  variant protein is covalently linked to said solid phase.
35. The method of claim 32, wherein said compound is selected from the group consisting of agonists, antagonists, antibodies, small molecules, and proteins.
36. An artificial array of GPCRs functionally coupled to the  $G_q$  variant of claim 1, wherein said array is a model of a native arrangement of GPCRs.

37. The artificial array of claim 36, wherein said native arrangement is an arrangement of olfactory receptors (ORs) typically seen in a mammalian nose.

38. The artificial array of claim 36, wherein said native arrangement is an arrangement of taste receptors typically seen on a mammalian tongue.

39. The artificial array of claim 38, wherein said taste receptors include at least one type of taste receptor selected from the group consisting of bitter, sweet, salty, unami and sour taste receptors.

**Fig. 1.** Alignment of amino acid sequences of human  $G\alpha_q$ ,  $G\alpha_{15}$  and  $G\alpha_{16}$  by Clustal method. The matched residues are marked in shaded box. The sequence accession number in the GenBank database is AAB06875, P30678, and P30679 for  $hG\alpha_q$ ,  $G\alpha_{15}$  and  $G\alpha_{16}$  respectively.

1	M T L E S I M A C C - - - L S E E A K E A R R I N D E I E R Q L R R D K R D A R	hGq
1	M A A R S L T W R C C P W C L T E D E K A A A R V D Q E I N R T L L E Q K K Q D R	G15
1	M A A R S L T W R C C P W C L T E D E K A A A R V D Q E I N R T L L E Q K K Q D R	G16
38	R E L K L L L L L G T G E S G K S T F I K Q M R I I H G S G Y S D E D K R G F T K	hGq
41	E E L K I L L L L G P G E S G K S T F I K Q M R I I H G V G Y S E E D R R A F R L	G15
41	G E L K L L L L L G P G E S G K S T F I K Q M R I I H G A G Y S E E E E K K G R R P	G16
78	L I Y Q N I F V S M Q A M I D A M D R L Q I P F S R E D S K Q H A S L V M T Q D	hGq
81	L I Y Q N I F V S M Q A M I D A M D R L Q I P F S R E D S K Q H A S L V M T Q D	G15
81	L V Y Q N I F V S M R A M I E A M E R L Q I P F S R E E S K H H A S L V M S Q D	G16
118	V E K V S A F E N P Y V D A I K S L W N D P G I Q E C Y D R E E E Y Q I S D S I T	hGq
121	P Y K V T T F E K R Y A A A M Q W L W R D A G I R A C Y E R R R E F H L L D S A	G15
121	P Y K V T T F E K R Y A A A M Q W L W R D A G I R A C Y E R R R E F H L L D S A	G16
158	K Y Y L N D L D R V A D P A Y L P T Q Q D V L R V R V E T T G T I E Y P E D L Q	hGq
161	V Y Y L S H L E R I S E D S Y I P T A Q D V L R S R M P T T G I N E Y C E S V K	G15
161	V Y Y L S H L E R I T E E G Y V P T A Q D V L R S R M P T T G I N E Y C E S V Q	G16
198	S V I F R M V D V G G Q R S E R R K W I H C F E N V T S I M F L V A L S E Y D Q	hGq
201	K T K L R I V D V G G Q R S E R R K W I H C F E N V I A L I Y L A S L S E Y D Q	G15
201	K T N L R I V D V G G Q K S E R R K W I H C F E N V T A L I Y L A S L S E Y D Q	G16
238	V E V E S D N E N R M E E S K A G R R I T Y P W Q N S S V V L M N N K K D	hGq
241	C L E E N D Q E N R M E E S L A L E S T I L E L P W E K S T S V I L F L N K T D	G15
241	C L E E N N Q E N R M K E S L A L E G T I L E L P W E K S T S V I L F L N K T D	G16
278	L L E E K Y M Y S H L V D Y E E Y D S P Q R D A Q A A R E E L L K M F V D L -	hGq
281	I L E E K I P T S H L A T Y F P S F Q G P K Q D A E A A K R F I L D M Y T R M Y	G15
281	I L E E K I P T S H L A T Y F P S F Q G P K Q D A E A A K R F I L D M Y T R M Y	G16
317	- - - N P D S D K I N - - - - Y S H F T C A T D T E N I R F V F A A V K	hGq
321	A S C A E P Q D G G R K G S R A R R F E A H E T C A T D T Q S V R S V E K D V R	G15
321	T G C V D G P E G S K K G A R S R R L F S H Y T C A T D T Q N I R K V F K D V R	G16
346	D T I L Q L N L K E Y N L V	hGq
361	D S V L A R Y L D E T N L L	G15
361	D S V L A R Y L D E T N L L	G16

Fig. 2. Amino acid sequences of the mouse and human  $G\alpha_q$

1 = mouse

2 = human

1MTLESIMACCLSEEAKEARRINDEIERQRRDKRDARRELKLLLLGTGESGK  
STFIKQMRIIHGSGYSDE  
2MTLESIMACCLSEEAKEARRINDEIERQRRDKRDARRELKLLLLGTGESGK  
STFIKQMRIIHGSGYSDE

DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNK AHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNK AHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG

IQECYDRRREYQLSDSTKY YLNDLDRVADPSYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
IQECYDRRREYQLSDSTKY YLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR

SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE

EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ

LNLKEYNLV  
LNLKEYNLV

Key amino acids described in this invention are boxed  
Difference between human and mouse is underlined

**Fig. 3.** Amino acid sequences of the mouse and human  $G\alpha_q$  proteins tested. Variation of amino acids of  $G\alpha_q$  is depicted in parenthesis. The sequence numbers of amino acid H or Q, V or L are 28 and 29 respectively. The sequence number of amino acid G or D is 66. Truncation of N-terminal six amino acids (MTLESI) are shown as  $\Delta N$ . Hemagglutinin (HA) epitope tag (DVPDYA) spans from 125 to 130. C-terminal five amino acids (-t5) or 44 amino acids (-t44) of transducin and five amino acids of  $G\alpha_{olf}$  (-olf5) are used respectively to replace those of  $G\alpha_q$ .

Mouse sequences created and tested:

Sequence ID#1

MGq

MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITiYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIiYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#2

mGq( $\Delta N$ )

MACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITiYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIiYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#3  
mGq(HA)

MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNI FTAMQAMIRAMDTLKIPYKYEHNK AHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKY YLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS DKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#4  
mGq( $\Delta$ N-HA)

MACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSGYSDE  
DKRGFTKL VYQNI FTAMQAMIRAMDTLKIPYKYEHNK AHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKY YLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS DKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#5  
mGq( $\Delta$ N-HVD-HA) from Kostenis et al 1998

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNI FTAMQAMIRAMDTLKIPYKYEHNK AHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKY YLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS DKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV



Sequence ID#6  
mGq( $\Delta$ N-HVD-HA)-t5

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLLNDLDRVADPSYLPQTQDVL RVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#7  
mGq( $\Delta$ N-HVD-HA)-t44

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLLNDLDRVADPSYLPQTQDVL RVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDNMRRDVKEIYSHMTCA  
TDTQNVKFVFDVTDIIK  
ENLKDCGLF

Sequence ID#8  
mGq( $\Delta$ N-HVG-HA)

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLLNDLDRVADPSYLPQTQDVL RVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLV ALSEYDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#9  
mGq(HVG-HA)

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#10  
mGq(D-HA)

MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#11  
mGq(HVD-HA)

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFR TIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#12  
mGq(HVG-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#13  
mGq(HVD-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#14  
mGq( $\Delta$ N-HVD-HA)-olf5

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPSYLP TQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKQYELL

## Human Sequences Tested

Sequence ID#15

HGq

MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTHITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNAV

Sequence ID#16

hGq( $\Delta$ N)

MACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAAHAQLVREVDVEKV  
SAFENPYVDAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTHITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNAV

Figure 4. Other sequences predicted by this invention active in assays of chemosensory receptors such as those GPCRs involved in sensing of tastants, olfactants and pheromones.

Sequence ID#17  
hGq( $\Delta$ N-HVD-HA)

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#18  
hGq( $\Delta$ N-HVD-HA)-t5

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#19  
hGq( $\Delta$ N-HVD-HA)-t44

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLVRVPPTTGIEYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDNMRRDVKEIYSHMTCA  
TDTQNVKFVFDVTDIIK  
ENLKDCGLF

Sequence ID#20  
hGq(D-HA)

MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLVRVPPTTGIEYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#21  
hGq(HVD-HA)

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLVRVPPTTGIEYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKEYNLV

Sequence ID#22  
hGq(HVG-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#23  
hGq(HVD-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKDCGLF

Sequence ID#24  
hGq( $\Delta$ N-HVD-HA)-olf5

MACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKSTFIKQM  
RIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYLYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRTIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKQYELL

Sequence ID#25  
hGq(HVG-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSGYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKQYELL

Sequence ID#26  
hGq(HVD-HA)-t5

MTLESIMACCLSEEAKEARRINDEIERHVRRDKRDARRELKLLLLGTGESGKS  
TFIKQMRIIHGSDYSDE  
DKRGFTKL VYQNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKV  
SAFDVPDYAAIKSLWNDPG  
IQECYDRRREYQLSDSTKYYLNDLDRVADPAYLPTQQDVLRVRVPTTGII EYP  
FDLQSVIFRMVDVGGQR  
SERRKWIHCFENVTSIMFLValseyDQVLVESDNENRMEESKALFRtIITYPW  
FQNSSVILFLNKKDLLE  
EKIMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDSDKIIYSHFTCATD  
TENIRFVFAAVKDTILQ  
LNLKQYELL